552
Participants
Start Date
March 26, 2021
Primary Completion Date
December 19, 2023
Study Completion Date
October 9, 2024
Pharmacogenetic test
Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
Lancaster General Hospital, Lancaster
Penn Presbyterian Medical Center, Philadelphia
University of Pennsylvania, Philadelphia
Abramson Cancer Center at Penn Medicine
OTHER